Abbratech Inc is a pioneering life science company based in Branford, Connecticut. Founded in 2020 by a team of experienced researchers, Abbratech is dedicated to revolutionizing the antibody development paradigm. Their EPIVOLVEsm technology enables the discovery, engineering, and validation of precision antibodies with exceptional specificity and accuracy, targeting specific sites on antigens at an almost amino acid resolution. With a focus on addressing the challenges in the research, pharmaceutical, and diagnostic markets, Abbratech offers comprehensive custom recombinant antibody development services, including antigen and project design, antibody optimization, and production.
Driven by continued innovation and leveraging knowledge gained from human genome sequencing and antibody engineering, Abbratech combines in vivo and in vitro methods, such as phage display and small animal B-cell cloning, to produce high affinity and highly specific recombinant antibodies. Their team of experienced scientists, with expertise in phage display, immunorepertoire analysis, and B cell cloning, ensures the successful development of antibodies against difficult antigen targets. Led by CEO and Founder, Michael P Weiner, Ph.D., Abbratech is poised to make significant advancements in the field of antibody discovery and engineering.
Generated from the website